Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15907MR)

This product GTTS-WQ15907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15907MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ711MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ3202MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ5132MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ6655MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ5057MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ2473MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ12004MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ15326MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW